Semaglutide Drugs Market size was valued at USD 4.1 Billion in 2024 and is projected to reach USD 15.5 Billion by 2033, exhibiting a CAGR of 16.5% from 2026 to 2033.
The South Korean Semaglutide Drugs Market is experiencing remarkable growth, driven by increasing demand from both diabetic and weight management sectors. Semaglutide, a GLP-1 receptor agonist, has emerged as a pivotal treatment option, significantly impacting the pharmaceutical landscape.
In 2023, the South Korean GLP-1 receptor agonist market generated revenues of approximately USD 217.9 million, with projections indicating a rise to USD 1,008.6 million by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 24.5% from 2024 to 2030. Notably, Ozempic (semaglutide) was the leading revenue-generating product in 2023, underscoring its dominance in the market.
Semaglutide's efficacy in weight management has further bolstered its market presence. In 2024, the GLP-1 agonists weight loss drugs market in South Korea was valued at USD 122.8 million, with expectations to reach USD 386.1 million by 2030. This segment is projected to grow at a CAGR of 16.7% from 2025 to 2030, with semaglutide (Wegovy) being the largest revenue-generating drug in 2024. The introduction of Wegovy, a higher-dose semaglutide formulation, has demonstrated superior efficacy, achieving an average weight reduction of 14.9% over 68 weeks in clinical trials, compared to 7.5% with Saxenda (liraglutide). This has significantly enhanced its appeal among patients seeking effective weight loss solutions.
Regional variations within South Korea also influence the market dynamics. Urban areas like Seoul and Incheon have reported higher diabetes prevalence, leading to increased demand for diabetes management solutions, including semaglutide. The government's investment in healthcare infrastructure in these regions has improved access to such treatments, further driving market growth.
Recent strategic partnerships have also impacted the market landscape. In May 2024, Biocon entered into an exclusive licensing and supply agreement with Handok to commercialize liraglutide, another GLP-1 receptor agonist, in South Korea. This collaboration aims to expand the availability of effective obesity treatments, complementing the existing offerings in the market.
In summary, the South Korean semaglutide drugs market is poised for substantial growth, propelled by increasing demand from both the diabetes and weight management sectors. The introduction of advanced formulations like Wegovy, strategic industry partnerships, and government initiatives to enhance healthcare infrastructure are key factors contributing to this expansion. As the market evolves, stakeholders must navigate regulatory landscapes, address manufacturing challenges, and meet the growing expectations of a health-conscious population seeking effective therapeutic options.
Get an In-Depth Research Analysis of the South Korea Semaglutide Drugs Market Size And Forecast [2025-2032]
Novo Nordisk
Huadong Medicine
Shanghai Benemae Pharmaceutical
Aurisco
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the South Korea Semaglutide Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the South Korea Semaglutide Drugs Market
Injectable Semaglutide
Oral Semaglutide
Type 2 Diabetes Treatment
Weight Management
Cardiovascular Risk Reduction
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Direct Sales
Hospitals
Clinics
Homecare Settings
Nursing Facilities
Pens
Vials
Tablets
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ South Korea Semaglutide Drugs Market Research Analysis
1. Introduction of the South Korea Semaglutide Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. South Korea Semaglutide Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. South Korea Semaglutide Drugs Market, By Type
6. South Korea Semaglutide Drugs Market, By Application
7. South Korea Semaglutide Drugs Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. South Korea Semaglutide Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/